VolitionRx (VNRX) Forward P/S Multiple

Brandmark of VolitionRx Ltd (VNRX)

VolitionRx Limited (VNRX) is facing slow clinical adoption of its tests and costly research. The business's prosperity relies on the accuracy of early blood-based cancer analysis and insurance coverage. Revenue growth is tied to the commercialization of epigenetic methods to reach break-even. The projected P/S ratio from the GURU.Markets terminal confirms these trends, with the parameter stabilizing at 2.00.

VNRX VolitionRx Ltd: Market Cap to Expected Sales Ratio in the range 07/04/2022 - 11/13/2026

VNRX (volition.com): analytical breakdowns and indicator data

- market price and analyst price targets:
Price Chart VolitionRx|VNRX - Analyst Median Target
- market capitalization details:
Market Capitalization VolitionRx Limited|VNRX - Company Buyout Price
- issuer book value statistics:
Net Assets per Single Share VolitionRx|VNRX - Book Valuation of Business|Market Cap to Net Assets Ratio volition.com|VNRX - Aggregate Company Assets
- company liabilities and liquidity data:
Debt to Equity VolitionRx Limited|VNRX - Long-Term Liabilities to Capital|Short-Term Debt to Equity VolitionRx|VNRX - Company Debts|Debts to Book Capitalization VolitionRx Limited|VNRX - Long-Term Debt Volume|Company Current Liabilities VolitionRx|Quick Ratio volition.com
- business earnings and investment ratios data:
VNRX - Net Financial Result|Expected Profit VolitionRx Limited|VNRX - Market Cap to Earnings|Future Price to Earnings VolitionRx|VNRX - Growth-Adjusted P/E Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization VolitionRx Limited|VNRX - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months VolitionRx|VNRX - Earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months volition.com|VNRX - Earnings per share increase in current year|Net earnings per share growth forecast for next year VolitionRx Limited
- sales volume and revenue indicators:
VNRX - Company Revenue|Projected Sales Volume VolitionRx|VNRX - Price-to-Revenue Coefficient|Price-to-Projected Revenue Ratio VolitionRx Limited
Summary company analytics:VolitionRx Ltd VNRX
Original product of VolitionRx

To assess the credit quality of VolitionRx Limited (VNRX), the analyst compares the issuer's market value with projected revenue, utilizing the company's P/S expectations to determine the extent of the growth premium currently priced in. The sustainability of this valuation is bolstered by the implementation of ethical ESG standards in cancer diagnostics, where waste minimization and data protection drive the asset's long-term investment attractiveness.

Analysis of competing companies

Price-to-Projected Revenue Ratio Caris Life Sciences CAI|Market Cap to Expected Sales Ratio Guardant Health Inc (GH)|Veracyte Corp - Forward P/S Multiple|Market Cap to Expected Sales Ratio Celcuity Therapeutics CELC|GRAIL, Inc. (GRAL) - Price-to-Projected Revenue Ratio|MYGN - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple CSTL|Price-to-Projected Revenue Ratio BNR|Price-to-Projected Revenue Ratio Biodesix Corp (BDSX)|PRPO - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Check-Cap CHEK|Mainz Biomed NV - Price-to-Projected Revenue Ratio|OncoCyte - Forward P/S Multiple